Multiple infliximab biosimilar switches appear to be safe and effective in a real‐world inflammatory bowel disease cohort

Disease Monitoring in Inflammatory Bowel Disease: Evolving Principles and Possibilities

(2022) Nikolas Plevris et al.   GASTROENTEROLOGY

Systematic Review and Meta-analysis: Loss of Response and Need for Dose Escalation of Infliximab and Adalimumab in Ulcerative Colitis

(2022) Edo H J Savelkoul et al.   INFLAMMATORY BOWEL DISEASES

Safety and clinical efficacy of the double switch from originator infliximab to biosimilars CT‐P13 and SB2 in patients with inflammatory bowel diseases (SCESICS): A multicenter cohort study

(2021) Stefano Mazza et al.   CTS-Clinical and Translational Science

Multiple Switches From the Originator Infliximab to Biosimilars Is Effective and Safe in Inflammatory Bowel Disease: A Prospective Multicenter Cohort Study

(2021) Jurij Hanzel et al.   INFLAMMATORY BOWEL DISEASES

Switching from Biosimilar to Biosimilar Adalimumab, Including Multiple Switching, in Crohn’s Disease: A Prospective Study

(2021) Davide Giuseppe Ribaldone et al.   Journal of Clinical Medicine

Trends in the use of biologicals and their treatment outcomes among patients with inflammatory bowel diseases – a Danish nationwide cohort study

(2021) Mirabella Zhao et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

The SPOSIB SB2 Sicilian Cohort: Safety and Effectiveness of Infliximab Biosimilar SB2 in Inflammatory Bowel Diseases, Including Multiple Switches

(2020) Fabio Salvatore Macaluso et al.   INFLAMMATORY BOWEL DISEASES

Effects of Successive Switches to Different Biosimilars Infliximab on Immunogenicity in Chronic Inflammatory Diseases in Daily Clinical Practice

(2020) Ambre Lauret et al.   SEMINARS IN ARTHRITIS AND RHEUMATISM

Normalization of Fecal Calprotectin Within 12 Months of Diagnosis is Associated with Reduced Risk of Disease Progression in Patients with Crohn’s Disease

(2020) N. Plevris et al.   Clinical Gastroenterology and Hepatology

Phase III randomized study of the proposed adalimumab biosimilar GP2017 in psoriasis: impact of multiple switches

(2018) A. Blauvelt et al.   BRITISH JOURNAL OF DERMATOLOGY

Biosimilars for the Management of Inflammatory Bowel Diseases: Economic Considerations

(2017) Laszlo Gulacsi et al.   CURRENT MEDICINAL CHEMISTRY

Biosimilars in the therapy of inflammatory bowel diseases

(2014) Tibor Hlavaty et al.   EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY

Correlation Between the Crohn's Disease Activity and Harvey–Bradshaw Indices in Assessing Crohn's Disease Severity

(2010) Severine Vermeire et al.   Clinical Gastroenterology and Hepatology